Walter

Walter Global Asset Management announces a new investment in Saranac Partners, a boutique European multi-family office

Retrieved on: 
Tuesday, March 26, 2024
Walter, CIO, Partnership, Culture, Growth, Ecosystem

MONTRÉAL, March 26, 2024 /CNW/ - Walter Global Asset Management ("Walter GAM") is proud to announce an investment in Saranac Partners ("Saranac"), an independent European multi-family office delivering personalized advice across a broad spectrum of wealth management services to help ultra-high-net-worth individuals and families deploy and access capital.

Key Points: 
  • MONTRÉAL, March 26, 2024 /CNW/ - Walter Global Asset Management ("Walter GAM") is proud to announce an investment in Saranac Partners ("Saranac"), an independent European multi-family office delivering personalized advice across a broad spectrum of wealth management services to help ultra-high-net-worth individuals and families deploy and access capital.
  • Founded in 2017, Saranac offers high-net-worth individuals and families the services of a team of independent and multidisciplinary experts, dedicated to protecting their interests.
  • "We identified Walter GAM as a preferred partner because of our shared vision of long-term partnership and collaboration," says Michelle Witter, Co-Chief Executive at Saranac.
  • Richard Berliand, Chair at Saranac, added "in Walter GAM we have found a partner that shares our culture, ambition, and ethos.

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference

Retrieved on: 
Wednesday, March 20, 2024
Lucid, Washington Convention Center, Walter, GERD, Esophagus, Cancer, Abstract, DDW, Barrett's esophagus, Assessment, Annual general meeting

NEW YORK, March 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that four abstracts related to its groundbreaking technologies, including its EsoGuard® Esophageal DNA Test, have been accepted for presentation by it and its collaborators at this year's Digestive Disease Week (DDW) Annual Meeting 2024—the world's premier meeting for digestive disease professionals.

Key Points: 
  • NEW YORK, March 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that four abstracts related to its groundbreaking technologies, including its EsoGuard® Esophageal DNA Test, have been accepted for presentation by it and its collaborators at this year's Digestive Disease Week (DDW) Annual Meeting 2024 —the world's premier meeting for digestive disease professionals.
  • "We are excited that our technologies will be prominently featured in multiple presentations at this year's DDW conference," said Suman Verma, M.D., Ph.D., Lucid Senior Vice President, and Chief Scientific Officer.
  • DDW 2024 will be held at the Walter E. Washington Convention Center in Washington, D.C., May 18 to 24, 2024.
  • Details on the time and location of the presentations will be provided prior to the conference.

Reticulate Micro to Exhibit at SATELLITE 2024

Retrieved on: 
Thursday, March 14, 2024
Reticulation, Washington Convention Center, SATCOM, Conference, SIG, EVP, Environment, Walter, VAST, Pleo, Glass, Exhibition, Breakfast, Video game

PALM BAY, Fla., March 14, 2024 /PRNewswire/ -- Reticulate Micro, Inc., a commercial and defense technology company dedicated to delivering trusted and resilient communications over any transport and in any environment, announced that it will exhibit at the SATELLITE 2024 Conference and Exhibition, hosted in Washington, D.C. at the Walter E. Washington Convention Center, March 19-21.

Key Points: 
  • PALM BAY, Fla., March 14, 2024 /PRNewswire/ -- Reticulate Micro, Inc., a commercial and defense technology company dedicated to delivering trusted and resilient communications over any transport and in any environment, announced that it will exhibit at the SATELLITE 2024 Conference and Exhibition , hosted in Washington, D.C. at the Walter E. Washington Convention Center, March 19-21.
  • VAST is Reticulate Micro's open-standards, software-defined encoder that delivers higher compression and lower bitrates capability without reliance on hubs or cloud services.
  • Reticulate Micro is solving this long-languishing inability to orchestrate terminal commissioning, command and control that has only been partially implemented until now.
  • SATELLITE marks Reticulate's first major industry tradeshow since announcing its SATCOM-focused business segment, Reticulate Space.

CopaSAT Debuts Military-Grade Starshield and Starlink-Enabled STORM V3 COTM Terminals at SATELLITE 2024

Retrieved on: 
Wednesday, March 13, 2024
LEO, Washington Convention Center, SATCOM, Communication, ESA, Wi-Fi, Walter, Business, Satellite, COTM, COTP, Starlink, Government, Communications satellite

SEMINOLE, Fla., March 13, 2024 /PRNewswire-PRWeb/ -- Today CopaSAT LLC (CopaSAT) announced its STORM V3 satellite communication (SATCOM) terminal engineered for commercial, government, military, and national security operations. The electronically steered antenna (ESA) boasts high-throughput data rates of up to 200Mbps downlink and 20Mbps uplink in a shock-resistant, IP68-rated package of only 23"x20"x2.65" and a weight of less than 30 pounds (13.6 Kg). It is easy to deploy with auto-provisioning and no commissioning required anywhere in the world with a service plan and attaches to vehicles and vessels via standard mounting systems. STORM V3 provides flexible connectivity via a mobile hotspot that can utilize SD-WAN to select between cellular, Wi-Fi, or satellite networks for optimization, failover, or balancing.

Key Points: 
  • SEMINOLE, Fla., March 13, 2024 /PRNewswire-PRWeb/ -- Today CopaSAT LLC (CopaSAT) announced its STORM V3 satellite communication (SATCOM) terminal engineered for commercial, government, military, and national security operations.
  • "As the demand for resilient, low-latency satellite communication solutions intensifies, CopaSAT has designed the STORM V3 terminal that integrates state-of-the-art technology including the Starlink and Starshield antenna systems."
  • "As the demand for resilient, low-latency satellite communication solutions intensifies, CopaSAT has designed the STORM V3 terminal that integrates state-of-the-art technology including the Starlink and Starshield antenna systems.
  • To coordinate a demonstration of STORM V3 in advance of Satellite 2024, contact CopaSAT at [email protected] .

World Vaccine Congress Draws Leaders from Government, Science and Industry

Retrieved on: 
Monday, March 11, 2024
Convention center, Bee, Washington Convention Center, Congress, Walter, Global health, Mayo Clinic, Food and Drug Administration, Cancer, International, Science Advisory Board, World Health Organization, Immunization, Vaccination, Bangladesh Technical Education Board, Vaccine, Food, Pharmaceutical industry

WASHINGTON, March 11, 2024 /PRNewswire/ -- The world's top experts and policymakers, including government leaders, renown researchers and company executives driving vaccine development, will gather to discuss the latest progress in vaccines — from efforts to inoculate bees to a discussion of pathogens that could cause the next pandemic — at the World Vaccine Congress April 1-4.

Key Points: 
  • "We have assembled the world's foremost experts and policymakers in the field of vaccination for the 2024 World Vaccine Congress," said Dr. Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and a member of the Science Advisory Board.
  • "This event represents an unparalleled opportunity for collaboration and innovation and promises to drive meaningful progress in global health.
  • It is a unique and massive forum for discovery and access to leaders across the field."
  • In-depth sessions also cover vaccine supply and logistics, veterinary vaccines, emerging diseases, and vaccine delivery.

OBSI announces new board members

Retrieved on: 
Friday, March 1, 2024
University of Toronto, Bank of Montreal, Trillium, University, University of British Columbia, Osgoode Hall Law School, Associate, Woman, Royal Bank of Canada, Fellow, Ethics, Bank, CFA, Information, Community, Retail, Royal Bank, Financial regulation, Toronto Life, Capital market, Regulation, HSBC Bank Canada, Ontario Securities Commission, Business, Ombudsman, CAIA, Walter, Knowledge, Commission, Commissioner, Insurance, Complaint, Central bank, Government, OSC, Distinguishing

TORONTO, March 01, 2024 (GLOBE NEWSWIRE) -- The Board of Directors for the Ombudsman for Banking Services and Investments (OBSI) is pleased to announce four appointments to the board:

Key Points: 
  • TORONTO, March 01, 2024 (GLOBE NEWSWIRE) -- The Board of Directors for the Ombudsman for Banking Services and Investments (OBSI) is pleased to announce four appointments to the board:
    Mary Condon has joined the board as a Consumer Interest Director.
  • Previously, she was a board member of the Capital Markets Authority Implementation Organization, and Commissioner and board member of the Ontario Securities Commission (OSC), where she was also a Vice-Chair.
  • All directors have a fiduciary duty to OBSI and do not advocate for or represent any outside interest while engaged in OBSI governance.
  • If a consumer has a complaint against an OBSI participating bank or investment firm that they are not able to resolve with the bank or firm, OBSI will investigate at no cost to the consumer.

BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment

Retrieved on: 
Friday, February 23, 2024
Incidence, AAAAI, Pharmacy, Attack, Expert network, Tranexamic acid, Prior, Effectiveness, Pharmacist, Washington Convention Center, University, Conditional sentence, Day, Lanadelumab, Safety, Androgen, HAE, History, Hereditary angioedema, Tolerability, Monitoring, Internal medicine, Walter, BioCryst Pharmaceuticals, Medicine, Disease, Ageing, Observational study, Poster, American Academy, Pharmaceutical industry

“These additional analyses of real-world use of ORLADEYO show that any person living with HAE has the potential to experience a rapid, substantial and sustained reduction in their monthly attack rate with ORLADEYO.

Key Points: 
  • “These additional analyses of real-world use of ORLADEYO show that any person living with HAE has the potential to experience a rapid, substantial and sustained reduction in their monthly attack rate with ORLADEYO.
  • These analyses present the overall attack rate progression and attack rate progression stratified by severity (i.e., number of attacks at baseline), prior prophylaxis and C1-INH level and function.
  • These findings further demonstrate that ORLADEYO can help maintain disease control in patients with lower baseline attack rates and further reduce attack rates in patients with more active disease.
  • Berotralstat Prophylaxis Reduces HAE Attack Rates Regardless of Baseline Attacks: Real-World Outcomes; Poster #012; Friday, February 23, 3:15-4:15 p.m.

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Retrieved on: 
Thursday, February 22, 2024
Bradykinin receptor B2, AAAAI, ODT, Hereditary angioedema, Attack, Safety, Washington Convention Center, EST, Reason (argument), Angioedema, HAE, Death, Abstract, Journal, Walter, Asthma, Science, Patient satisfaction, American Academy, Pharmaceutical industry

CHAPTER-1 is a two-part, Phase 2 study evaluating the efficacy, safety, and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and type 2 (HAE-1/2).

Key Points: 
  • CHAPTER-1 is a two-part, Phase 2 study evaluating the efficacy, safety, and tolerability of deucrictibant for long-term prophylaxis against angioedema attacks in HAE type 1 and type 2 (HAE-1/2).
  • 34 participants were treated with double-blinded study drug (placebo or deucrictibant, 20 or 40 mg/day) for 12 weeks of treatment.
  • “These data validate the mechanism of deucrictibant to provide early and sustained protection from HAE attacks.
  • By better understanding and addressing these factors, we aspire to make our commitment to ‘pioneering science for patient choice’ a reality.”

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

Retrieved on: 
Tuesday, February 20, 2024
PEOPLE, BAT, DBV Technologies, AAAAI, Immunotherapy, Safety, EST, Peanut allergy, Toddler, FIT, Longitudinal, Convention center, D.C, Associate, Walter, Patient, Clinical trial, Pediatrics, Asthma, Food, Diagnosis, DBV, Ageing, American Academy, Pharmaceutical industry

DBV is sponsoring a non-CME Product Theater titled “Importance of Early Intervention for Peanut Allergy.” Professors Hugh Sampson, M.D.

Key Points: 
  • DBV is sponsoring a non-CME Product Theater titled “Importance of Early Intervention for Peanut Allergy.” Professors Hugh Sampson, M.D.
  • DBV will host a booth (#567) in the AAAAI exhibit hall where attendees can learn more about epicutaneous immunotherapy with Viaskin, including our ongoing clinical trials in peanut-allergic children.
  • Chief Medical Officer at DBV Technologies.
  • “DBV, is committed to generating robust, long-term safety data with Viaskin Peanut to aid in future shared decision-making.

AST SpaceMobile Announces Participation in Upcoming Conferences

Retrieved on: 
Tuesday, February 20, 2024
Technology, Satellite, Aerospace, Manufacturing, Mobile, Wireless, Telecommunications, ASTS, Washington Convention Center, Conference, The, Mobile World Congress, Walter, Congress, Mobile phone

AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, today announced participation in the following upcoming industry and investor conferences:

Key Points: 
  • AST SpaceMobile, Inc. (“AST SpaceMobile”) (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, today announced participation in the following upcoming industry and investor conferences:
    Mobile World Congress, taking place on Monday, February 26 to Thursday, February 29 at the Fira Gran Via in Barcelona, Spain
    32nd Annual Deutsche Bank Media, Internet & Telecom Conference, taking place on Monday, March 11 at The Breakers Hotel in Palm Beach, FL.
  • Management will host investor meetings throughout the day
    36th Annual ROTH Conference, taking place on Monday, March 18 at The Ritz-Carlton Laguna Niguel in Dana Point, CA.
  • Management will host investor meetings throughout the day
    SATELLITE 2024, taking place on Tuesday, March 19 to Wednesday, March 20 at the Walter E. Washington Convention Center in Washington, DC